RxSight, Inc. (NASDAQ:RXST) Director Purchases $504,106.07 in Stock

RxSight, Inc. (NASDAQ:RXST) Director Jesse Anderson Corley purchased 11,111 shares of the stock in a transaction dated Tuesday, November 12th. The shares were acquired at an average price of $45.37 per share, with a total value of $504,106.07. Following the transaction, the director now owns 468,571 shares in the company, valued at $21,259,066.27. This trade represents a 2.43 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

RxSight Stock Up 2.0 %

Shares of RxSight stock opened at $45.05 on Friday. RxSight, Inc. has a 12 month low of $27.07 and a 12 month high of $66.54. The stock’s fifty day simple moving average is $50.32 and its 200 day simple moving average is $53.28.

Analyst Upgrades and Downgrades

A number of analysts have commented on RXST shares. Oppenheimer lowered their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. Stifel Nicolaus reduced their price target on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Wells Fargo & Company dropped their price objective on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Jefferies Financial Group initiated coverage on RxSight in a report on Tuesday, October 29th. They set a “buy” rating and a $72.00 target price on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $66.00 target price on shares of RxSight in a research report on Friday, September 13th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, RxSight has an average rating of “Buy” and a consensus target price of $61.63.

Institutional Investors Weigh In On RxSight

Hedge funds have recently modified their holdings of the business. Brown Capital Management LLC bought a new stake in RxSight during the 3rd quarter worth approximately $26,813,000. Point72 Asset Management L.P. increased its position in shares of RxSight by 610.2% during the third quarter. Point72 Asset Management L.P. now owns 446,976 shares of the company’s stock worth $22,094,000 after acquiring an additional 384,041 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of RxSight during the second quarter worth $19,512,000. Driehaus Capital Management LLC lifted its position in RxSight by 74.9% in the 2nd quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock valued at $42,490,000 after acquiring an additional 302,367 shares in the last quarter. Finally, Baillie Gifford & Co. boosted its stake in RxSight by 438.8% in the 2nd quarter. Baillie Gifford & Co. now owns 358,215 shares of the company’s stock worth $21,554,000 after purchasing an additional 291,733 shares during the period. Institutional investors and hedge funds own 78.78% of the company’s stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.